NCT01106716

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: KAI Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain

Conditions

• Postherpetic Neuralgia

Interventions

Type	Name	Description
DRUG	Placebo	Placebo IV Infusion
DRUG	KAI-1678	KAI-1678 IV Infusion
DRUG	Lidocaine	Lidocaine

Timeline

• Start date: 2009-03-01
• Primary completion: 2010-03-01
• Completion: 2010-04-01
• First posted: 2010-04-20
• Last updated: 2025-09-02

Locations

1 site across 1 country: Australia